iCAD, Inc. (ICAD)
NASDAQ: ICAD · Real-Time Price · USD
1.890
+0.030 (1.61%)
Nov 7, 2024, 4:00 PM EST - Market closed
iCAD, Inc. Revenue
iCAD, Inc. had revenue of $5.03M in the quarter ending June 30, 2024, with 20.57% growth. This brings the company's revenue in the last twelve months to $18.80M, up 7.40% year-over-year. In the year 2023, iCAD, Inc. had annual revenue of $17.32M, down -12.54%.
Revenue (ttm)
$18.80M
Revenue Growth
+7.40%
P/S Ratio
2.59
Revenue / Employee
$272,391
Employees
69
Market Cap
49.81M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 17.32M | -2.48M | -12.54% |
Dec 31, 2022 | 19.80M | -13.84M | -41.13% |
Dec 31, 2021 | 33.64M | 3.94M | 13.27% |
Dec 31, 2020 | 29.70M | -1.64M | -5.24% |
Dec 31, 2019 | 31.34M | 5.72M | 22.32% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Cytosorbents | 37.16M |
Rapid Micro Biosystems | 26.17M |
Aadi Bioscience | 25.07M |
SCYNEXIS | 8.57M |
LAVA Therapeutics | 7.40M |
OncoCyte | 1.02M |
ICAD News
- 1 day ago - iCAD to Attend 15th Annual Craig-Hallum Alpha Select Conference - GlobeNewsWire
- 22 days ago - iCAD to Participate in the LD Micro Main Event XVII - Newsfile Corp
- 5 weeks ago - iCAD Highlights Global Availability of ProFound Cloud and International Expansion Milestones at JFR 2024 - GlobeNewsWire
- 3 months ago - iCAD, Inc. (ICAD) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - iCAD Reports Financial Results for Second Quarter Ended June 30, 2024 - GlobeNewsWire
- 3 months ago - iCAD and Windsong Radiology Announce Strategic Commercial Agreement to Implement AI-Powered Mammography - GlobeNewsWire
- 4 months ago - iCAD to Highlight Promising Research on Potential of its AI Algorithm to More Accurately Identify and Personalize Breast Cancer Risk at SIIM 2024 - GlobeNewsWire
- 5 months ago - iCAD to Participate in the MedInvest MedTech, AI & Digital Health Conference - GlobeNewsWire